PFE/Merck KGaA: found this news somewhat surprising. With Tecentriq, Opdivo and soon to be Keytruda (which will have a full approval with randomized OS no less) and durvalumab from AZ, didn't think FDA would accept yet another filing. My understanding is that the avelumab filing is based on Phase 1b data that looks pretty much the same as all the rest.
News 
Market Data 
Discover 
